Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) EBT (2016 - 2025)

Catalyst Pharmaceuticals' EBT history spans 16 years, with the latest figure at $71.9 million for Q4 2025.

  • For Q4 2025, EBT fell 3.07% year-over-year to $71.9 million; the TTM value through Dec 2025 reached $283.5 million, up 31.1%, while the annual FY2025 figure was $283.5 million, 31.1% up from the prior year.
  • EBT reached $71.9 million in Q4 2025 per CPRX's latest filing, up from $71.0 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $74.2 million in Q4 2024 to a low of -$38.0 million in Q3 2023.
  • Average EBT over 5 years is $37.6 million, with a median of $35.2 million recorded in 2022.
  • Peak YoY movement for EBT: tumbled 246.2% in 2023, then surged 250.46% in 2024.
  • A 5-year view of EBT shows it stood at $12.8 million in 2021, then surged by 157.61% to $33.0 million in 2022, then soared by 41.5% to $46.7 million in 2023, then skyrocketed by 58.82% to $74.2 million in 2024, then dropped by 3.07% to $71.9 million in 2025.
  • Per Business Quant, the three most recent readings for CPRX's EBT are $71.9 million (Q4 2025), $71.0 million (Q3 2025), and $69.3 million (Q2 2025).